Topical 10% tranexamic acid for erythematotelangiectatic steroid-induced rosacea.

J Am Acad Dermatol

Department of Dermatology and Sexually Transmitted Diseases, North Delhi Municipal Corporation Medical College and Hindu Rao Hospital, New Delhi, India.

Published: January 2022

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.12.067DOI Listing

Publication Analysis

Top Keywords

topical 10%
4
10% tranexamic
4
tranexamic acid
4
acid erythematotelangiectatic
4
erythematotelangiectatic steroid-induced
4
steroid-induced rosacea
4
topical
1
tranexamic
1
acid
1
erythematotelangiectatic
1

Similar Publications

Aim: To analyse the clinical and demographic profiles of patients with vernal keratoconjunctivitis (VKC) and propose a grading for VKC based on corneal status and symptom periodicity rather than disease activity.

Methods: Retrospective observational study from January 2015 to January 2020 in India. VKC grading was based on past/present clinical signs and frequency of symptoms rather than disease activity.

View Article and Find Full Text PDF

Clinical, Laboratory, and Trichoscopic Features of Pediatric Androgenetic Alopecia.

Cutis

December 2024

Drs. Lu, Du, Zhao, and Fan and Lingbo Bi, Chaofan Wang, and Yunbu Ding are from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China. Yige Fan is from the Mayo Clinic, Rochester, Minnesota.

Article Synopsis
  • The study reviewed 133 pediatric patients over 14 years to understand the prevalence and effects of androgenetic alopecia (AGA), with symptoms appearing as early as age 10.
  • Factors such as BMI, family history, comorbidities, and hair loss patterns were examined, revealing differences in trichoscopic outcomes between sexes and age groups.
  • The research emphasizes the need for personalized treatment plans for AGA in children, suggesting the use of topical minoxidil while ensuring close monitoring and encouraging adherence to medication and follow-ups for better results.
View Article and Find Full Text PDF

Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.

Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.

View Article and Find Full Text PDF

Acne vulgaris (AV) is a common chronic inflammatory skin disorder that commonly lasts from adolescence to adulthood and has serious social and psychological consequences. Current treatments typically use antibacterial drugs, which contributes to the rise in antibacterial drug resistance. Spironolactone, a potassium-sparing diuretic with anti-androgen effects, has been used off-label to treat acne by lowering sebum production.

View Article and Find Full Text PDF

Background: Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder marked by eosinophilic infiltration of the esophageal mucosa. Despite advances in understanding and management, optimal therapeutic strategies remain unclear, with conflicting guidelines.

Objective: We sought to evaluate effectiveness and safety of topical corticosteroids (TCSs) and proton pump inhibitors (PPIs) in managing EoE and their economic implications in Italy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!